Back to Search
Start Over
Levodopa/carbidopa intestinal gel can improve both motor and non-motor experiences of daily living in Parkinson's disease: An open-label study.
- Source :
-
Parkinsonism & Related Disorders . Apr2017, Vol. 37, p79-86. 8p. - Publication Year :
- 2017
-
Abstract
- <bold>Background: </bold>Levodopa/carbidopa intestinal gel therapy (LCIG) can efficiently improve several motor and non-motor symptoms of advanced Parkinson's disease (PD). The recently developed Movement Disorder Society-sponsored Unified Parkinson's Disease Rating Scale (MDS-UPDRS) improved the original UPDRS making it a more robust tool to evaluate therapeutic changes. However, previous studies have not used the MDS-UPDRS and the Unified Dyskinesia Rating Scale (UDysRS) to assess the efficacy of LCIG.<bold>Objectives: </bold>Our aim was to determine if the MDS-UPDRS and UDysRS could detect improvement in the experiences of daily living following 1-year LCIG treatment.<bold>Methods: </bold>In this prospective, multicenter, open-label study, 34 consecutive patients undergoing LCIG treatment were enrolled. Patients were examined twice: prior to LCIG initiation and 12 months later. Impact of PD-related symptoms and dyskinesia was assessed by the MDS-UPDRS and UDysRS.<bold>Results: </bold>Non-motor Experiences of Daily Living part of MDS-UPDRS improved from 20 (median, interquartile-range, IQR:14-23) to 16 points (median, IQR:12-20, p = 0.044) and the Motor Experiences of Daily Living ameliorated from 24 (median, IQR:20-29) to 18 points (median, IQR:13-25, p = 0.025). Health-related quality of life, measured by PDQ-39, also improved from 35.4 (median, IQR:26.9-50.3) to 27.0 (median, IQR:21.3-31.4) points (p = 0.003). The total score of UDysRS decreased from 47 (median, IQR:36-54) to 34 (median, IQR:21-45) points (p = 0.003).<bold>Conclusions: </bold>As far as the authors are aware of, our paper is the first to evaluate the impact of LCIG on dyskinesia by the means of UDysRS. Changes in MDS-UPDRS and UDysRS confirm that LCIG treatment can efficiently improve experiences of daily living in advanced PD. [ABSTRACT FROM AUTHOR]
- Subjects :
- *PARKINSON'S disease treatment
*CARBIDOPA
*DOPA
*DRUG efficacy
*QUALITY of life
*THERAPEUTICS
*INTESTINAL physiology
*DRUG therapy for Parkinson's disease
*PARKINSON'S disease
*DOPAMINE agents
*PHARMACEUTICAL gels
*ANTIPARKINSONIAN agents
*COMBINATION drug therapy
*COMPARATIVE studies
*FUNCTIONAL assessment
*LONGITUDINAL method
*RESEARCH methodology
*MEDICAL cooperation
*QUESTIONNAIRES
*RESEARCH
*ACTIVITIES of daily living
*EVALUATION research
*TREATMENT effectiveness
*SEVERITY of illness index
*PSYCHOLOGY
Subjects
Details
- Language :
- English
- ISSN :
- 13538020
- Volume :
- 37
- Database :
- Academic Search Index
- Journal :
- Parkinsonism & Related Disorders
- Publication Type :
- Academic Journal
- Accession number :
- 121997199
- Full Text :
- https://doi.org/10.1016/j.parkreldis.2017.02.001